|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:Japan
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:brand
|
Remitch
|
|
gptkbp:CASNumber
|
152658-17-8
|
|
gptkbp:chemicalFormula
|
C21H26ClN3O2
|
|
gptkbp:developedBy
|
gptkb:Toray_Industries
|
|
gptkbp:has_stereochemistry
|
(2R)
|
|
gptkbp:hasSMILES
|
CN(C)C1CCC(CC1)C(=O)N(C)CC2=CC(=C(C=C2)Cl)Cl
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nalfurafine
|
|
gptkbp:indication
|
treatment of pruritus in chronic kidney disease
treatment of pruritus in chronic liver disease
|
|
gptkbp:isNotApprovedIn
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:IUPACName
|
N-[(2R)-2-(3,4-dichlorophenyl)ethyl]-N-methyl-4-(methylamino)cyclohexanecarboxamide
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only (Japan)
|
|
gptkbp:mechanismOfAction
|
kappa-opioid receptor agonist
|
|
gptkbp:molecularWeight
|
387.9 g/mol
|
|
gptkbp:PubChem_CID
|
CHEMBL2103887
9941952
DB11611
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
hallucination
fatigue
headache
insomnia
dysphoria
|
|
gptkbp:UNII
|
6T6J2J95HK
|
|
gptkbp:bfsParent
|
gptkb:kappa-opioid_receptor
|
|
gptkbp:bfsLayer
|
7
|